Mease et al. PsA - Early DMARD initiators (=<1 year following diagnosis) greater improvement in outcomes than late initiators (at least in MDA) in CorEvitas. @RheumNow #ACR22 Abstr#1493 https://t.co/oadxbG8TKS https://t.co/245xVTcKx1
Links:
Impact of Delay of Treatment with Disease Modifying Antirheumatic Drugs (DMARDs…
https://acrabstracts.org/abstract/impact-of-delay-of-treatment-with-disease-mod…
13-11-2022
